Inspire Medical Systems (NYSE:INSP – Get Free Report) was upgraded by Freedom Capital to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.
INSP has been the topic of several other reports. Piper Sandler lowered Inspire Medical Systems from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $85.00 to $55.00 in a research note on Tuesday, May 5th. Zacks Research downgraded Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 13th. Wells Fargo & Company decreased their price objective on Inspire Medical Systems from $70.00 to $56.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 5th. Summit Redstone set a $39.00 price objective on Inspire Medical Systems in a research report on Friday, May 22nd. Finally, Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 target price for the company. in a research note on Friday, May 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Inspire Medical Systems presently has a consensus rating of “Hold” and a consensus target price of $81.05.
View Our Latest Analysis on INSP
Inspire Medical Systems Price Performance
Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its quarterly earnings data on Monday, May 4th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to the consensus estimate of $200.04 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. The business’s revenue was up 1.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.10 EPS. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Analysts expect that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Inspire Medical Systems
Several institutional investors have recently added to or reduced their stakes in the company. Xponance Inc. increased its holdings in Inspire Medical Systems by 2.9% in the 3rd quarter. Xponance Inc. now owns 4,177 shares of the company’s stock worth $310,000 after acquiring an additional 116 shares during the last quarter. Daiwa Securities Group Inc. lifted its holdings in Inspire Medical Systems by 38.7% during the second quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after purchasing an additional 130 shares during the last quarter. State of Wyoming lifted its holdings in Inspire Medical Systems by 31.5% during the fourth quarter. State of Wyoming now owns 731 shares of the company’s stock valued at $67,000 after purchasing an additional 175 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after purchasing an additional 205 shares during the period. Finally, Apollon Wealth Management LLC increased its stake in shares of Inspire Medical Systems by 5.6% in the first quarter. Apollon Wealth Management LLC now owns 3,997 shares of the company’s stock worth $206,000 after purchasing an additional 212 shares in the last quarter. 94.91% of the stock is owned by institutional investors.
Inspire Medical Systems Company Profile
Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.
The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.
Featured Stories
- Five stocks we like better than Inspire Medical Systems
- Shorting the Grid: Bloom Energy’s $25B AI Power Play
- SanDisk’s Volatility May Be Telling Bulls What They Want to Hear
- Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon
- 3 Dividend ETFs Built for Stability in a Volatile Market
Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
